Fatty liver disease affects approximately one in three UK adults, prompting many to explore complementary approaches including cannabidiol (CBD). Whilst laboratory studies suggest CBD may influence liver metabolism and inflammation, there is currently no established clinical evidence that CBD helps fatty liver disease in humans. No CBD product holds regulatory approval from the MHRA or EMA for treating hepatic steatosis. This article examines the current research, proven treatments recommended by NICE, and important safety considerations for anyone considering CBD alongside evidence-based lifestyle interventions for fatty liver disease.

Understanding Fatty Liver Disease and Its Causes

Fatty liver disease, medically termed hepatic steatosis, occurs when excess fat accumulates in liver cells. In the UK, this condition affects approximately one in three adults and represents a growing public health concern. The condition exists in two primary forms: non-alcoholic fatty liver disease (NAFLD) and alcohol-related liver disease (ARLD), with alcohol-related fatty liver representing the early stage of ARLD.

Non-alcoholic fatty liver disease develops in individuals who consume little to no alcohol. It encompasses a spectrum of conditions, from simple steatosis (fat accumulation without inflammation) to non-alcoholic steatohepatitis (NASH), where inflammation and liver cell damage occur. NASH can progress to fibrosis, cirrhosis, and ultimately liver failure or hepatocellular carcinoma. The primary risk factors include:

• Obesity and overweight (particularly central adiposity)

• Type 2 diabetes mellitus and insulin resistance

• Metabolic syndrome (hypertension, dyslipidaemia, elevated blood glucose)

• Sedentary lifestyle and poor dietary habits

• Polycystic ovary syndrome (PCOS)

Alcohol-related fatty liver results from excessive alcohol consumption over time. The liver metabolises alcohol, but chronic intake overwhelms this capacity, leading to fat deposition, inflammation, and cellular injury. According to NHS guidance, regularly exceeding 14 units of alcohol weekly increases risk significantly.

Most individuals with early-stage fatty liver disease remain asymptomatic. The condition is often detected incidentally through abnormal liver function tests or imaging performed for other reasons. As the disease progresses, patients may experience fatigue, right upper quadrant discomfort, or hepatomegaly.

NICE guidance (NG49) recommends investigating patients with persistent liver enzyme elevation or metabolic risk factors using validated non-invasive fibrosis scores in primary care. The FIB-4 score or NAFLD Fibrosis Score should be calculated initially. If these indicate indeterminate or high risk of advanced fibrosis, the Enhanced Liver Fibrosis (ELF) test is recommended to identify those requiring specialist referral. Transient elastography (FibroScan) may be used in secondary care settings to assess liver stiffness and estimate fat content (via controlled attenuation parameter, or CAP), though availability and interpretation vary. Other causes of liver disease—including viral hepatitis, autoimmune hepatitis, haemochromatosis, and Wilson's disease—should be excluded where clinically appropriate.

What Is CBD and How Does It Work in the Body?

Cannabidiol (CBD) is one of over 100 naturally occurring compounds called cannabinoids found in the Cannabis sativa plant. Unlike tetrahydrocannabinol (THC), the psychoactive component of cannabis, CBD does not produce intoxication or euphoria. In the UK, CBD itself is not a controlled substance, but THC and certain other cannabinoids are controlled under the Misuse of Drugs Act 1971. Consumer CBD products should not contain detectable levels of controlled cannabinoids and must comply with Home Office and Food Standards Agency (FSA) requirements.

Mechanism of action: CBD interacts with the body's endocannabinoid system (ECS), a complex cell-signalling network involved in regulating numerous physiological processes including metabolism, inflammation, immune response, and pain perception. The ECS comprises endogenous cannabinoids (endocannabinoids), cannabinoid receptors (primarily CB1 and CB2), and enzymes that synthesise and degrade these molecules.

CB1 receptors are predominantly located in the central nervous system and liver, whilst CB2 receptors are found mainly in immune cells and peripheral tissues. CBD exhibits low affinity for these receptors but modulates the ECS indirectly. Preclinical research suggests CBD may:

• Inhibit fatty acid amide hydrolase (FAAH), the enzyme that breaks down anandamide (an endocannabinoid), thereby increasing endocannabinoid levels

• Act on non-cannabinoid receptors including serotonin (5-HT1A), vanilloid (TRPV1), and peroxisome proliferator-activated receptors (PPARs)

• Demonstrate anti-inflammatory and antioxidant properties through multiple pathways

These mechanistic findings are derived largely from laboratory and animal studies. The pharmacological complexity of CBD means that such findings do not necessarily translate to clinical efficacy in humans, and rigorous clinical trials remain essential to establish any therapeutic role. Dosing used in animal models often far exceeds typical human supplement intakes, and the relevance of these doses to human use is uncertain.

Current Research on CBD and Fatty Liver Disease

Research examining CBD's effects on fatty liver disease remains predominantly preclinical, with most evidence derived from animal models and in vitro studies. There is currently no established clinical evidence that CBD improves fatty liver disease in humans, and no CBD product holds regulatory approval for this indication from the MHRA or European Medicines Agency (EMA).

Preclinical evidence: Laboratory studies have suggested several potentially beneficial mechanisms. Research in rodent models of NAFLD has demonstrated that CBD administration may reduce hepatic steatosis, decrease inflammatory markers, and improve insulin sensitivity. Proposed mechanisms include:

• Reduction of lipogenesis (fat synthesis) through modulation of metabolic pathways

• Enhanced autophagy (cellular self-cleaning processes) in hepatocytes

• Anti-inflammatory effects via reduction of pro-inflammatory cytokines

• Antioxidant properties that may protect against oxidative stress-induced liver damage

• Modulation of gut-liver axis and intestinal permeability

Studies in mice fed high-fat diets have reported reductions in liver fat accumulation and changes in genes involved in lipid metabolism and fibrosis development. However, the doses used in these animal studies often exceed those found in typical human CBD supplements, and the relevance to human disease remains unclear.

Human evidence: Clinical trials specifically investigating CBD for fatty liver disease in humans are extremely limited. The existing human studies on CBD have focused primarily on epilepsy (where the prescription medicine Epidyolex is licensed for specific epilepsy syndromes), anxiety, and pain management. No robust, randomised controlled trials have evaluated CBD's efficacy or safety for treating NAFLD or ARLD in human populations.

Importantly, clinical trials of high-dose prescription CBD (Epidyolex) for epilepsy have identified elevations in liver enzymes in some patients, raising safety concerns for individuals with existing liver disease. This underscores the need for caution and further research.

Healthcare professionals should counsel patients that whilst laboratory research shows theoretical promise, translating these findings to clinical practice requires substantial further investigation, including properly designed human trials assessing dosing, safety, long-term outcomes, and potential drug interactions.

Proven Treatments for Fatty Liver Disease in the UK

NICE guidance (NG49) emphasises that lifestyle modification remains the cornerstone of fatty liver disease management, with evidence-based interventions focusing on addressing underlying metabolic dysfunction. Currently, no pharmacological therapy holds specific UK approval for treating NAFLD, though several medications are under investigation or used off-label in specialist settings.

First-line management strategies recommended by NICE include:

• Weight reduction: A 7–10% reduction in body weight can significantly improve hepatic steatosis and inflammation. Even modest weight loss (3–5%) provides metabolic benefits.

• Dietary modification: Mediterranean-style diets rich in vegetables, fruits, whole grains, and healthy fats (olive oil, nuts) whilst limiting refined carbohydrates, saturated fats, and processed foods.

• Physical activity: At least 150 minutes of moderate-intensity aerobic exercise weekly, combined with resistance training, improves insulin sensitivity and reduces liver fat independent of weight loss.

• Alcohol cessation: Complete abstinence for alcohol-related liver disease; limiting intake to within recommended guidelines (no more than 14 units weekly, spread over three or more days) for NAFLD patients.

Management of comorbidities is essential:

• Diabetes control: Optimising glycaemic management with metformin as first-line therapy. Pioglitazone may improve liver histology in selected patients with biopsy-proven NASH, though weight gain and other adverse effects require consideration. GLP-1 receptor agonists (such as semaglutide), licensed for type 2 diabetes and obesity under existing NICE guidance, may offer weight-loss benefits and improvements in liver fat.

• Cardiovascular risk reduction: Statins are safe in fatty liver disease and should be prescribed according to cardiovascular risk assessment. They do not worsen liver disease.

• Hypertension and dyslipidaemia management following standard guidelines.

Additional therapeutic considerations:

• Vitamin E may be considered for adults with biopsy-proven NASH (without diabetes or cirrhosis), though this is off-label use and potential risks (including increased all-cause mortality at high doses) must be discussed.

• Bariatric surgery may be appropriate for patients with severe obesity who meet eligibility criteria, and can lead to significant improvements in liver disease.

Assessment and referral pathway (NICE NG49):

In primary care, calculate the FIB-4 score or NAFLD Fibrosis Score for patients with suspected NAFLD. If the score indicates indeterminate or high risk of advanced fibrosis, arrange an Enhanced Liver Fibrosis (ELF) test. Refer to a specialist hepatology service if:

• ELF score suggests advanced fibrosis (typically ≥10.51, though local thresholds may vary)

• Persistently abnormal liver function tests despite lifestyle intervention

• Diagnostic uncertainty or suspicion of alternative liver disease

• Consideration for emerging therapies or clinical trials

Transient elastography (FibroScan) may be used in secondary care to further assess liver stiffness and fat content, with interpretation guided by validated cut-offs and clinical context.

Urgent assessment is required if patients develop:

• Jaundice (yellowing of skin or eyes)

• Abdominal swelling (ascites)

• Confusion or altered mental state (hepatic encephalopathy)

• Vomiting blood or passing black, tarry stools (gastrointestinal bleeding)

• Rapidly worsening symptoms

Patients experiencing severe symptoms such as significant bleeding, acute confusion, or collapse should call 999 or attend A&E immediately. For new or worsening jaundice, abdominal swelling, or significant fatigue, contact your GP urgently for same-day assessment.

Safety Considerations and Legal Status of CBD in the UK

Legal status: In the UK, CBD itself is not a controlled substance, but THC and certain other cannabinoids are controlled under the Misuse of Drugs Act 1971. Consumer CBD products must not contain detectable levels of controlled cannabinoids and must comply with Home Office regulations. Since 31 March 2021, CBD products require authorisation as Novel Foods from the Food Standards Agency (FSA) to be legally sold as food supplements. The FSA maintains a CBD Public List of products with validated novel food applications that are permitted to remain on the market whilst their applications are assessed. Consumers should verify that products appear on this list and purchase from reputable suppliers providing third-party laboratory testing certificates.

CBD is not licensed as a medicine for fatty liver disease or most other conditions in the UK. The exception is Epidyolex (prescription cannabidiol), which is licensed only for specific epilepsy syndromes and is available only on prescription. Products sold as food supplements cannot make medicinal claims.

FSA safety advice: The FSA recommends that healthy adults limit CBD intake to no more than 10 mg per day unless under medical supervision. CBD should be avoided during pregnancy and breastfeeding due to potential risks to the developing baby.

Safety considerations for patients considering CBD include:

• Hepatotoxicity concerns: Paradoxically, high-dose CBD has demonstrated potential liver toxicity in some studies. Clinical trials of prescription CBD (Epidyolex) for epilepsy have identified elevated liver enzymes in some patients, particularly at higher doses. Patients with existing liver disease, including fatty liver, should exercise particular caution and discuss use with their GP or hepatologist before starting CBD.

• Drug interactions: CBD inhibits cytochrome P450 enzymes (particularly CYP3A4 and CYP2C19) and may affect P-glycoprotein transport, potentially altering the metabolism of numerous medications. This includes warfarin, immunosuppressants (tacrolimus, ciclosporin), some antiepileptic drugs (clobazam), and certain statins. This may increase drug levels and the risk of adverse effects. Patients taking any regular medication should consult their GP or pharmacist before using CBD.

• Quality and contamination: Unregulated or non-compliant products may contain inaccurate CBD concentrations, undeclared THC, pesticides, heavy metals, or other contaminants. Only purchase products on the FSA CBD Public List.

• Adverse effects: Commonly reported effects include diarrhoea, fatigue, changes in appetite, and drowsiness. Do not drive or operate machinery if you feel drowsy or impaired.

Patient advice: Individuals with fatty liver disease should not use CBD as a substitute for proven lifestyle interventions such as weight loss, dietary improvement, and increased physical activity. Those considering CBD should:

• Discuss with their GP or hepatologist before starting, particularly if taking other medications or if liver disease is present

• Avoid CBD if pregnant, breastfeeding, or planning pregnancy

• Purchase only products listed on the FSA CBD Public List from reputable sources with third-party testing

• Adhere to the FSA recommendation of no more than 10 mg CBD per day for healthy adults

• Monitor for adverse effects and report concerns to healthcare providers

The MHRA Yellow Card scheme (yellowcard.mhra.gov.uk) allows reporting of suspected side effects from CBD products and all medicines, contributing to ongoing safety monitoring. If you experience any suspected adverse reaction, please report it via the Yellow Card scheme.

Key resources:

• NICE NG49: Non-alcoholic fatty liver disease (assessment and management)

• NHS: Non-alcoholic fatty liver disease (NAFLD)

• FSA: CBD consumer advice and the FSA CBD Public List

• Home Office: Cannabis, CBD and other cannabinoids guidance

• MHRA Yellow Card scheme: yellowcard.mhra.gov.uk

Frequently Asked Questions